These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 21687625)
1. Biomarkers in overactive bladder: a new objective and noninvasive tool? Antunes-Lopes T; Carvalho-Barros S; Cruz CD; Cruz F; Martins-Silva C Adv Urol; 2011; 2011():382431. PubMed ID: 21687625 [TBL] [Abstract][Full Text] [Related]
2. Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome. Kuo HC Low Urin Tract Symptoms; 2012 Mar; 4 Suppl 1():32-41. PubMed ID: 26676698 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in overactive bladder. Bhide AA; Cartwright R; Khullar V; Digesu GA Int Urogynecol J; 2013 Jul; 24(7):1065-72. PubMed ID: 23314226 [TBL] [Abstract][Full Text] [Related]
4. Can urinary nerve growth factor be a biomarker for overactive bladder? Kuo HC; Liu HT; Chancellor MB Rev Urol; 2010; 12(2-3):e69-77. PubMed ID: 20811555 [TBL] [Abstract][Full Text] [Related]
5. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Wang LW; Han XM; Chen CH; Ma Y; Hai B Int Urol Nephrol; 2014 Feb; 46(2):341-7. PubMed ID: 23982767 [TBL] [Abstract][Full Text] [Related]
6. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. Tsiapakidou S; Apostolidis A; Pantazis K; Grimbizis GF; Mikos T Int Urogynecol J; 2021 Dec; 32(12):3143-3155. PubMed ID: 34363496 [TBL] [Abstract][Full Text] [Related]
7. [Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis]. Bazhenov IV; Filippova ES; Bazarnyi VV; Sazonov SV; Volkova LI; Zaitseva LN Urologiia; 2018 Jul; (3):44-48. PubMed ID: 30035417 [TBL] [Abstract][Full Text] [Related]
8. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. Liu HT; Chen CY; Kuo HC J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884 [TBL] [Abstract][Full Text] [Related]
9. Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019. Antunes-Lopes T; Cruz F Eur Urol Focus; 2019 May; 5(3):329-336. PubMed ID: 31231010 [TBL] [Abstract][Full Text] [Related]
10. Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. Kuo HC; Liu HT; Guan Z; Tyagi P; Chancellor MB Low Urin Tract Symptoms; 2011 Apr; 3(1):2-9. PubMed ID: 26676344 [TBL] [Abstract][Full Text] [Related]
11. What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Fry CH; Sahai A; Vahabi B; Kanai AJ; Birder LA Neurourol Urodyn; 2014 Jun; 33(5):602-5. PubMed ID: 24436105 [TBL] [Abstract][Full Text] [Related]
12. The profile of urinary biomarkers in overactive bladder. Rada MP; Ciortea R; Măluţan AM; Doumouchtsis SK; Bucuri CE; Clim A; Roman A; Mihu D Neurourol Urodyn; 2020 Nov; 39(8):2305-2313. PubMed ID: 32813897 [TBL] [Abstract][Full Text] [Related]
15. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Kuo HC; Liu HT; Chancellor MB Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641 [TBL] [Abstract][Full Text] [Related]
16. Urinary brain-derived neurotrophic factor and nerve growth factor as noninvasive biomarkers of overactive bladder in children. Colic M; Rogic D; Lenicek Krleza J; Kozmar A; Stemberger Maric L; Abdovic S Biochem Med (Zagreb); 2022 Oct; 32(3):030706. PubMed ID: 36277428 [TBL] [Abstract][Full Text] [Related]
17. Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder? Huseynov A; Telli O; Haciyev P; Okutucu TM; Akinci A; Ozkidik M; Erguder I; Fitoz S; Burgu B; Soygur T Int Braz J Urol; 2022; 48(3):553-560. PubMed ID: 35373950 [TBL] [Abstract][Full Text] [Related]
18. The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment? Alkis O; Zumrutbas AE; Toktas C; Aybek H; Aybek Z Neurourol Urodyn; 2017 Feb; 36(2):390-393. PubMed ID: 26661444 [TBL] [Abstract][Full Text] [Related]
19. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. Kim SR; Moon YJ; Kim SK; Bai SW Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766 [TBL] [Abstract][Full Text] [Related]
20. Can urinary nerve growth factor and bladder wall thickness correlation in children have a potential role to predict the outcome of non-monosymptomatic nocturnal enuresis? Telli O; Samancı C; Sarıcı H; Hascıcek AM; Kabar M; Eroglu M J Pediatr Urol; 2015 Oct; 11(5):265.e1-5. PubMed ID: 26051999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]